|
MEMORANDUM |
F
O R T H E
R E C O R
D |
|
|
|
Date: April 26, 2004
From: Biomedical Engineer
Orthopedic
Devices Branch
Division
of General, Restorative, and Neurological Devices
HHS/FDA/CDRH/ODE
Subject: Review Memo for Reclassification Petition for Mobile
Bearing Knees
To: The Record, Reclassification
Petition for Mobile Bearing Knees
Summary:
This
petition, sponsored by the Orthopedic Surgical Manufacturers Association
(OSMA), was officially filed on June 13, 2003.
An amendment to the petition, in response to the FDA deficiency letter
of February 18, 2004, was dated March 31, 2004, and received April 1,
2004.
This
petition seeks reclassification of mobile bearing knee prostheses from
post-amendment Class III Pre-Market Approval (PMA) status to Class II
Pre-Market Notification (510k) status. These mobile bearing knees are currently
Class III PMA devices. This petition breaks the mobile bearing knee prostheses
into two general groups: mobile bearing
total knees and mobile bearing unicompartmental knees.
Presented
in this petition are:
·
A brief introduction to the petition (see
Section I).
·
General device information and proposed intended
use (see Section II).
·
Proposed device descriptions for the Code of
Federal Regulations (CFR) (see Section III).
·
The regulatory history of the devices considered
for reclassification (see Section IV).
·
Basis for the petition (see Section V).
·
A summary of test results on wear, kinematics,
and biomechanics from more than 45 articles published in peer-reviewed journals
(see Sec. VI).
·
A summary of unpublished clinical data from
seven on-going investigational device exemption (IDE) clinical studies and two
large international clinical outcomes studies (see Section VII).
·
A summary of published clinical data from more
than 50 articles published in peer-reviewed journals, together with a
meta-analysis comparing clinical outcomes for different mobile bearing knees,
and a meta-analysis comparing survivorship of mobile bearing knees versus fixed
bearing knees (see Section VIII).
·
A listing of adverse events reported through the
FDA’s Medical Device Reporting (MDR) system (see Section IX).
·
A risk analysis, and suggested special controls
to address the identified risks, such as labeling, preclinical tests and test
methods (see Section X).
·
A list of mobile bearing knees currently or
previously on the market, including 46 devices that are available
internationally, five of which are also available in the U.S. (see Section XI).
·
Letters in support of the reclassification
petition from orthopedic surgeons (see Appendix 1).
·
A summary of published literature from more than
40 articles published in peer-reviewed journals on the subject of ‘wear in
total knee arthroplasty’ (see Appendix 1a of Amendment 1, Response to FDA
letter of 2/18/04).
·
A description of the many different types of
mobile bearing knee designs, their characteristics, biomechanical
advantages/disadvantages, survival rates, risks, and proposed controls (for the
identified risks) for each of the different device designs (see Appendix 1c,
Amendment 1, Response to FDA letter of 2/18/04).
·
A summary comparing the clinical results for
various mobile bearing knee device designs with fixed bearing devices (see
Appendix 1d, Amendment 1, Response to FDA letter of 2/18/04).
Intended Use:
It
is believed by FDA that patient indications for each device type (total knee
and unicompartmental knee) are sufficiently different to warrant separation of
the two devices.
Mobile
Bearing Total Knee
The
mobile bearing total knee is a device intended to be implanted to replace a
knee joint. The device is indicated for:
·
Patients with knee pain and disability due to
rheumatoid arthritis, osteoarthritis, traumatic arthritis, polyarthritis,
collagen disorders and/or avascular necrosis of the femoral condyle
·
Post-traumatic loss of joint configuration
(particularly when there is patellofemoral erosion, dysfunction, or prior
patellectomy)
·
Moderate valgus, varus, or flexion deformities
·
The salvage of previously failed surgical
attempts if the knee can be satisfactorily balanced and stabilized at the time
of surgery.
The
device may be used with or without bone cement.
No
further device design specific indications were provided for the various types
of mobile bearing total knees.
Mobile
Bearing Unicompartmental Knee
The
mobile bearing unicompartmental knee is a device intended to be implanted to
replace part (one compartment) of a knee joint. The device is indicated for:
·
Patients with knee pain and disability due to
osteoarthritis or traumatic arthritis
·
Previous tibial condyle or plateau fractures
with loss of anatomy or function
·
Varus or valgus deformities
·
Use with an intact anterior cruciate ligament
(ACL)
·
Revision of previous unicompartmental
arthroplasty procedures
The
device may be used with or without bone cement.
Device Description/Principle of
Operation:
The
sponsor has proposed the following classification description for mobile
bearing total knees and mobile bearing unicompartmental knees:
Mobile
Bearing Total Knee
‘Knee
joint patellofemorotibial metal/polymer mobile bearing cemented or porous
coated uncemented prosthesis’.
A
knee joint patellofemorotibial metal/polymer mobile bearing cemented or porous
coated uncemented prosthesis is a device intended to be implanted to replace a
knee joint. The device permits either
unconstrained or constrained rotation of the articular surface in the
transverse plane and may or may not permit limited anteroposterior and/or
mediolateral movement of the articular surface upon the tibial component. It has not linkage across the joint. The device may use affixed structural porous
metal in place of the porous coating.
This generic type of device is designed for use with bone cement and/or
to achieve biological fixation to bone without the use of bone cement.
Mobile
Bearing Unicompartmental Knee
‘Knee
joint femorotibial (unicompartmental) metal/polymer mobile bearing cemented or
porous coated uncemented prosthesis’.
A
knee joint femorotibial (unicompartmental) metal/polymer mobile bearing
cemented or porous coated uncemented prosthesis is a device intended to be
implanted to replace part of a knee joint. The device permits either
unconstrained or constrained rotation of the articular surface in the
transverse plane and may or may not permit limited anteroposterior and/or
mediolateral movement of the articular surface upon the tibial component. It has not linkage across the joint. The device may use affixed structural porous
metal in place of the porous coating. This
generic type of device is designed for use with bone cement and/or to achieve
biological fixation to bone without the use of bone cement.
Risk to Health /Special Controls
The
sponsor performed a search of the MDR reporting information on FDA’s MAUDE
website database which yielded 385 reports.
The dates searched ranged from November 15, 1993 to December 31, 2002. All hits were from the DePuy LCS Mobile
Bearing Knee System, the only approved mobile bearing knee system on the market
in the U.S. during this time. The 385
reports contained 365 adverse events, of which 333 were reported as injuries,
29 as malfunctions, 2 were other/no answer, and 1 report was submitted as a
death. The event descriptions are
included in Section IX. The greatest
number of adverse events were reported for pain (with effusion, hemarthrosis,
or swelling), fractured bearings, and loosening, respectively.
The
risks to health presented in this petition have been grouped into three general
categories: infection, adverse tissue
reaction, and loss or reduction of joint function/revision (see Section X).
These risks are evaluated in two tables using a common engineering tool, a
Failure Modes and Effects Analysis (FMEA).
Table 5 (in Section X) contains the hazards common to both fixed and
mobile bearing knees, while Table 6 contains hazards deemed specific to mobile
bearing knees, exclusively. Each hazard
(risk) is identified along with ways they can be controlled to reduce the
potential risk to the patient. Finally,
special controls are identified for each of the hazards. Many of the common
risks can be mitigated by material standards, proper device design, labeling,
Good Manufacturing Practices (GMP) and Quality System Regulations (QSR). As noted in Table 5, most risks identified
are common to both fixed and mobile bearing knees. Only two hazards were identified as unique to mobile bearing
knees, and they are related to ‘loss of reduction of joint
function/revision’. Specifically, the
potential for the mobile bearing to rotate beyond design objectives and the
potential for greater wear due to additional articulating surfaces were the
hazards cited as uniquely related to the design of mobile bearing knees.
The
sponsor believes that risks associated with mobile bearing knees are known, and
can be mitigated to acceptable levels with the general and special controls
available to the FDA for other class II knee devices (e.g., FDA guidance
documents, ASTM/ISO standards, labeling restrictions -
indications/contraindications/warnings, etc.) to provide reasonable assurance
of safety and efficacy. In addition,
suggested tests and test methods for mobile bearing knees are provided. In the original submission none of the
suggested testing differed from what is currently required by FDA for
evaluating fixed bearing knee devices.
However,
as noted in the tables in appendix 1c of the March 31, 2004, amendment, there
are numerous ‘sub-categories’ of the two types of mobile bearing knees
identified above. These include devices
with multidirectional platforms, rotating platforms, meniscal bearings,
tricompartmental (mobile bearing patella), bicompartmental (femorotibial –
total), unicompartmental, cone-in-cone, tibial tray post, longitudinal curved
tracks, with and without rotational stops, and all with varying levels of
femorotibial congruency. In Section XI
of the original submission the sponsor provides a listing of 46 mobile bearing
devices that are currently, or were, on the market either in the U.S. or
overseas. They represent a wide variety
of design approaches to mobile bearing knees, as noted above. In the U.S., only the DePuy LCS Rotating
Platform, LCS Meniscal Bearing, LCS Unicompartmental Knee, P.F.C. Sigma
Rotating Platform, P.F.C. Sigma Stabilized Rotating Platform, and Biomet’s
Oxford Meniscal Unicompartmental Knee have been approved for use.
Due
to the unique risks that may exist within each of the various designs it may
only be possible to evaluate these designs on a case by case basis. One set of special controls may not be
appropriate to encompass the whole range of mobile bearing knees. These concerns were addressed to OSMA in the
FDA letter of February 18, 2004. Their
March 31 amendment attempts to address these concerns.
In
response to the FDA questions posed in the 2/18/04 letter, the sponsor did
identify additional risks unique to mobile bearing knees. These included ‘spinout’ of the tibial
bearing insert, disassociation of the insert from the tibial tray, and insert
deformation due to overhang. The
sponsor also provided specifics on preclinical testing (special controls) to
address these risks. In appendix 1c of
the March 31, 2004, amendment, descriptions of preclinical testing to evaluate
characteristics unique to mobile bearing knees were provided. In particular, standardized wear test
methods originally developed for fixed bearing knees (ASTM F-1715 “Standard
Guide for Wear Assessment of Prosthetic Knee Designs in Simulator Devices, and
ISO 14243-1, “Implants for Surgery – Wear of total knee joint prostheses – Part
1: Loading and displacement parameters
for wear-testing with load control and corresponding environmental conditions
for test”) were noted along with two potential methods for evaluating backside
wear (wear between the tibial tray and tibial insert). It was also suggested that particulate
analysis (size/morphology/quantity) of wear particles be performed and compared
with that seen from a clinically successful predicate control to determine if
there is an increased risk of osteolysis due to the mobile bearing design
(i.e., dual articulating surfaces).
‘Spinout’ was noted as a risk unique to mobile bearing knees. ‘Spinout’ is defined as, “excessive rotation
of the tibial insert resulting from at least one femoral condyle riding up and
over the lip of the insert such that the femoral condyle disassociates from the
inserts articular surface”. The sponsor
states this should be evaluated to limit or eliminate the potential for bearing
spinout. They suggest it may be
assessed using modified constraint testing standard ASTM F-1223 (Standard Test
Method for Determination of Total Knee Replacement Constraint) after adapting
for physiologic compressive loads, rotary torques, and varus moments that are
deemed to be causative of insert spinout.
The
risks of disassociation of the insert from the tibial tray or increased
impingement of the insert against other portions of the device due to design
(e.g. sliding tracks, captured tibial tray posts, etc.) have also been
identified. The sponsor states that
this should be evaluated to determine that there is not an increased risk of
occurrence, and that a successful result (insert does not bind or disassociate
under physiological loads) would provide reasonable assurance that it will not
occur during normal use.
Overhang
deformation of the polyethylene tibial insert is another risk unique to mobile
bearing knees that was identified in the petition. Overhang refers to any portion of the tibial insert that is not
directly supported by the tibial tray.
Mobile bearing knees should be designed to limit overhang and/or tested
to determine if any overhang presents a new failure mechanism by restricting
rotation due to deformation or increasing wear due to deformation. Although there is no standard for this
evaluation, the sponsor suggests this can be assessed during knee simulator
wear testing.
The
sponsor also states that those mobile bearing knees that utilize a mechanical
stop to limit or eliminate rotation, spinout, or sliding movements should be
evaluated for polyethylene wear/fracture caused by contact with the stop. Again, modified wear simulator testing is
suggested as the method of evaluation.
In
summary, most of the preclinical testing identified for the mobile bearing
knees is the same type of testing currently asked by FDA for fixed bearing knee
devices (tibial tray fatigue, contact area/stress, constraint, etc.). For risks unique to mobile bearing knees
most of the ‘new’ testing suggested revolves around some sort of modified wear
simulator testing to evaluate a specific characteristic (i.e., particulate
analysis, overhang deformation, mechanical stop impingement, disassociation,
etc.). The hard part is going to be
actually defining what these modified tests are, and trying to determine
whether they are truly predictive from one mobile bearing design to another. Can reasonable assurance of safety and
efficacy for myriad device designs be made based on modifications to existing
test methods (e.g., knee simulator wear testing)? That is, are the proposed special controls (or others) adequate
to address the inherent risks of the mobile bearing knee designs (or some subset
of these knee designs) identified in this petition, and to provide reasonable
assurance of safety and effectiveness?
Although
labeling has been identified as a special control with which to address the
above risks to health, the proposed labeling requirements are consistent with
those generally found in current fixed bearing total and unicompartmental knee
package labeling. No specific labeling
requirements were identified for any of the mobile bearing specific risks.
Known Potential Benefits
No
specific benefits of mobile bearing knee prostheses were stated in this
petition, however, evidence has been provided to show that available long term
data suggests that mobile bearing devices are equally safe and effective as
compared with fixed bearing devices in total or unicompartmental knee
arthroplasty.
Dual
surface articulation between a polyethylene insert and metallic femoral and
tibial tray components are a consequence of mobile bearing knee designs. Their advantage may lay in the maximization
of femoral-tibial contact area which results in the attenuation of peak
stresses, minimizing the potential for UHMWPE damage. Additionally, the mobility of the tibial insert allows for
reduction of implant-bone interface torque contributing to in-vivo component
fixation longevity. An increasing
number of these designs are being utilized globally in total knee
reconstruction, particularly among younger age groups with degenerative joint
pathology.
Potential
benefits for both fixed and mobile bearing knees include a decrease or
cessation of pain, and increased mobility and function post-operatively as
compared to pre-operatively.
Summary of Clinical Data
Please
see Dr. Buch’s review memo for a complete evaluation of the clinical data
presented in this petition. Selected
series of 48 studies have been summarized in Table 7, 8, and 9 of appendix 3 of
the original submission. Data presented
includes available demographics, study design, safety, effectiveness, and
survivorship data. Included in these
tables are 4 studies for multidirectional mobile bearing knees, 4 for rotating
bearing knees, 8 for meniscal bearing knees, 11 for combination rotating
platform and meniscal bearing in same study, and 21 for unicompartmental
devices. Minimum follow-ups ranged from
roughly 2 years to 12 years. These experiences underscore the strong influence
of the technical performance of the operation on the long-term success of a
knee device. Properly aligned knee
arthroplasties that have restored ligament balance (medial and lateral, flexion
and extension) appear to have survival rates of ten years or greater,
irrespective of bearing mobility. These
data indicate that when provided with medial-lateral stabilization, mobile
bearing knees provide equivalent results as fixed bearing knees.
Bibliography and References
An extensive bibliography containing 193 citations was provided in
the original petition, which included case studies, well controlled
investigations, studies without matched controls, non-clinical bench studies,
and retrieval studies. In addition,
unpublished data from 7 ongoing IDE studies was provided. An additional 43
articles on wear were provided in the March 31, 2004, amendment.
Comments
A
number of orthopedic surgeons have provided letters expressing their desire to
include mobile bearing knees in their list of treatment options, particularly
for younger patients (appendix 1 of original submission).